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preservation, and the rapidly expanding recipient pool. Larger 
series will be required to critically evaluate the use of kidneys 
from the young donor less than two years old. 
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EFFECT OF THE IMMUNOSUPPRESSANT FK506 ON GLUCOSE-INDUCED INSULIN SECRETION FROM 
ADULT RAT ISLETS OF LANGERHANS 
The clinical use of cyclosporine has been a key advance in 
organ transplantation in the past decade (1). This agent is 
currently used in patients who receive all types of allografts. 
Also, CsA has been useful in preventing the onset of insulin-
dependent diabetes in animal models (2) and inducing remis-
sions in new-onset type I diabetes in humans (3). Despite the 
impressive achievements with cyclosporine, nephrotoxicity and 
graft rejection are still significant problems. Additionally, CsA 
decreases insulin synthesis and secretion in several species (4-
7) and decreases glucose induced insulin secretion from human 
islets in vitro (8). It has been reported to decrease intravenous 
glucose tolerance when compared with azathioprine used in the 
same patient (9). The long-term consequences of these findings 
continue to be of concern. 
FK506 is a new immunosuppressive agent that is more potent 
on a weight basis than CsA (10). These drugs share many 
similar effects although the binding proteins for these two 
agents appear to be different. The binding sites share a novel 
isomerase enzyme system: peptidyl proline isomerase, which 
may represent an important common site of action (J 1). FK506 
has recently been used successfully in trials in humans undergo-
ing organ transplantation (12). 
In baboons, others have raised the issue of its potential 
adverse effect on glucose tolerance (13). Preliminary studies in 
human recipients of liver allografts showed that 6/12 patients 
had oral glucose tolerance tests that deviated from normal at 
at least one time point; 2 patients had impaired glucose toler-
ance, but only one patient ha.d overt diabetes (14). These 
findings do not appear to differ from historical controls 
undergoing liver transplantation who did not receive FK506-
however, the question of the effect of this agent on glucose 
metabolism remains an important unanswered question. 
FK506 apparently does not alter morphology or interfere 
with insulin secretion from fetal islets of Langerhans (15). 
Glucose-induced insulin secretion in neonatal and fetal islets 
is not comparable to the adult response (J 6, 17). Since adult 
tissues are often used in transplant studies, we looked at the 
effect of FK506 on glucose-induced insulin secretion from adult 
rat islets of Langerhans. 
We used freshly isolated islets obtained by collagenase diges-
tion of the pancreas, from adult male Wistar rats (18). Insulin 
was measured by standard radioimmunoassay using a charcoal 
and dextran separation method (19). After isolation, islets were 
washed 5 times in basal (2.8 or 5.6 mM) glucose containing 
buffer. 
Acute drug exposure studies. We measured insulin released 
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FIGURE 1. The acute effect of FKS06 on 16.7 mM glucose-induced 
insulin release. In this and subsequent figures insulin release was 
measured at the end of a 90-min incubation in all conditions. Values 
are expressed as the mean ± SEM from 36 batches of islets. In this 
and subsequent figures, 100% secretion corresponds to insulin meas-
ured in 16.7 mM glucose after subtraction of basal release. Basal (2.8 
mM glucose induced) insulin release was 6S0±S.8 pg/islet/90 min and 
stimulated (16.7 mM glucose induced) release was 2208±20.9 pg/islet/ 
90 min (P<O.01). A concentration of 100 ng/ml FKS06 produced an 
average inhibition of 3S% (P<O.OS). This concentration was inhibitory 
in every experiment. In one experiment, a concentration of 10 ng/ml 
was also significantly inhibitory. 
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ACUTE EFFECT OF CYCLOSPORIN E A ON 
GLUCOSE INDUCED INSULIN SECRETION 
0 0.1 1.0 10 
CONCENTRATION CYCLOSPORINE A !",g/mll 
FIGURE 2. The acute effect of esA on glucose induced insulin re-
lease. Values are expressed as the mean ± SEM from 12 batches of 
islets. Basal (2.8 mM glucose induced) insulin release was 229±0.93 
pg/islet/90 min and stimulated (16.7 mM glucose induced) was ISS6± 
10.2 pg/islet/90 min (P<O.OI). esA at concentrations of 1 and 10 }Jog/ 
ml produced about a 30% inhibition of stimulated insulin release 
(P<O.OS). 
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FIGURE 3. The combined effect of esA and FKS06 on glucose-
induced insulin release. Results are expressed as the mean ± SEM 
from 12 batches of islets. Basal (2.8 mM glucose-induced) insulin 
release was 268±8.S pg/islet/90 min, and stimulated (16.7 mM glucose 
induced) release was 1288±11.4 pg/islet/90 min (P<O.OI). esA pro-
duced a 40% and SO% reduction of glucose-induced insulin release at 1 
and 10 }Jog/ml, respectively (P<0.05). The effects of esA at either 
concentration and FKS06 (1 ng/ml) were not additive to inhibit insulin 
release further. ~ 
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FIGURE 4. Effect of 24-hr incubation with immune suppressant 
drugs on glucose induced insulin release. After 24-hr culture in the 
presence of esA or FKS06 in the concentrations shown, the islets were 
washed sx then preincubated in 5.6 mM glucose contaiiring. buffer 
without drug. The medium was removed and insulin release was meas-
ured at the end of a 90-min incubation in all conditions. Values are 
expressed as the mean ± SEM from 12 batches of islets. Basal (5.6 
mM glucose-induced) insulin release was 236±3.4 pg/islet/90 min and 
stimulated (16.7 mM glucose-induced) release was 1020±6.9 pg/islet/ 
90 min (P<O.Ol). Previous exposure to esA produced a 33% inhibition 
(P<O.05) of glucose-induced insulin release. FKS06 did not produce a 
significant inhibition. 
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by 2.8 mM or 16.7 mM glucose during a 90-min static incuba-
tion of groups of 5-6 freshly isolated islets incubated in the 
presence or absence of CsA (provided by Sandoz Research 
Institute East Hanover, NJ), FK506 (provided by Dr. Raman 
Venkatarmanan, School of Pharmacy University of Pitts-
burgh), or a combination of these two agents. 
Incubation with immunosuppressive agents. For a 24-hour 
culture period, groups of 5 islets each were transferred to wells 
containing 1 ml of minimal essential culture medium (Biofluids, 
Rockville, MD), supplemented with 10% fetal calf serum. The 
medium was also supplemented with penicillin (100 units/ml) 
and streptomycin (100 ,ug/m!) and were maintained at 3TC in 
an atmosphere of 5% CO2, Groups of islets were maintained in 
the presence or absence of drugs, and after the 24 hr period 
were washed five times with 5.6 mM drug-free buffer and then 
preincubated in buffer containing 5.6 mM glucose for 1 hr 
without drug. After the preincubation, the medium was changed 
and we measured the insulin released by 5.6 or 16.7 mM glucose. 
For all experiments, a modified Krebs buffer was used and 
contained (mM): 120 NaCI, 5 KCI, 25 NaHC03, 2.5 CaCle, 1.l 
MgCI2 , equilibrated with 95% O2/5% CO2 and supplemented 
with 5 mg/ml bovine serum albumin, pH 7.4 at 3TC. 
Results are expressed as mean ± SEM. The statistical sig-
nificance of the insulin release data were analyzed by Student's 
t test. Data with multiple groups were analyzed using a one 
way analysis of variance (ANOVA) and the nonparametric 
Wilcoxon ranked sum test. Conclusions drawn from parametric 
and nonparametric analyses were the same. We used a stepwise 
multiple-comparisons procedure to assess dose-response results 
(20). 
In all experiments, glucose (16.7 mM) produced a marked 
rise in insulin secretion (3-7-fold) compared with basal (2.8 or 
5.6 mM) (P<O.Ol) (data not shown). 
Figure 1 summarizes the results of short-term incubations 
with FK506. Concentrations of 100 ng/ml produced a 35% 
inhibition of the 16.7 mM glucose-induced insulin release 
(P<0.05). This concentration produced a significant inhibition 
in every experiment. In one experiment a 10 ng/ml concentra-
tion was also clearly inhibitory (P<0.05). 
The results of acute (90-min) incubation with CsA are shown 
in Figure 2. C~AI at concentrations of 1 and 10 ,ug/ml, produced 
approximately a 30% inhibition of the glucose-induced insulin 
secretion (P<0.05). These results are similar to those obtained 
by others in studies using normal rat islets or an insulin-
secreting cell line (6). 
In animal studies the immune suppressant effects of cyclo-
sporine and FK506 appear to be additive (21). During graft 
rescue there may be a brief period of exposure to both drugs 
while being switched to FK50B. We therefore looked at the 
effect of a 90-min exposure to a combination of FK50B and 
CsA on glucose-induced insulin release. Figure 3 summarizes 
these results. CsA, 1 and 10 ,ug/ml, produced 40 and 50% 
reductions in glucose induced insulin release, respectively 
(P<0.05). Addition of 1 ng/ml FK50B did not produce an 
inhibition in addition to that obtained with cyclosporine alone. 
Figure 4 shows the results obtained after a 24-hr incubation 
in the presence of 10 ,ug/ml CsA compared with 1 and 10 ng/ 
ml FK506. After washing the islets with drug-free medium and 
an additional 1 hr preincubation in without drugs, the cyclo-
sporine-treated islets still showed a 34% decrease in the insulin 
response to IB.7 mM glucose IP<0.05). The insulin response 
in the FK506-treated islets was not significantly inhibited. 
In summary, the present study shows that FK50B inhibits 
insulin secretion at the highest concentrations used (10 and 
100 ng/ml). The amount of inhibition is similar to that pro-
duced by 1 and 10 ,ug/ml CsA. Since FK506 is a more potent 
agent, the serum levels required to suppress the immune re-
sponse are less than 5 ng/m!. The level of CsA, 1 ,ug/ml, that 
inhibited insulin secretion in our studies is within the range 
that we see in recipients of kidney, liver, and pancreas trans-
plants who are treated with CsA and steroids. The results of 
the combination study suggest that the effects of cyclosporine 
and FK506 on glucose-induced insulin secretion are not addi-
tive at lower concentrations of FK506. The results obtained on 
cultured islets (24 hr) suggest that, at lower concentrations of 
FK506, there is no inhibition, or that any inhibition of glucose-
induced insulin release produced by FK506 is quickly reversible. 
When used long-term intramuscularly, FK506 appeared to 
be diabetogenic in baboons (13). When the immunosuppression 
was changed at 4 days to an oral regimen, a diabetogenic effect 
was not observed in baboons undergoing renal transplantation 
(22) or in cynomolgus monkeys undergoing pancreaticoduode-
nal allotransplantation (23). FK506 appears to have a consid-
erable steroid-sparing effect (12). In that case, there may be 
fewer problems with the diabetogenic effect of this agent except 
when used intravenously or in very high concentrations. In 
addition, there are important species differences reported with 
side effects of this agent (24). Since there are potentially 
important applications of this drug in the field of diabetes, 
further studies of the long-term effects of FK506 on glucose 
metabolism in vitro and in vivo in human1 are required. 
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SUCCESSFUL ORTHOTOPIC LIVER TRANSPLANTATION IN A CHILD WITH LANGERHANS CELL 
HISTIOCYTOSIS l 
Langerhans ce,ll histiocytosis, previously termed "histiocy-
tosis X," is a rare, childhood disorder, characterized histologi-
cally by the proliferation of specialized dendritic (Langerhans) 
cells. Clinical presentation varies from benign localized involve-
ment to fulminant disseminated disease associated with high 
rates of morbidity and mortality. The latter presentation is 
seen most often in infants and young children with multisystem 
involvement and organ dysfunction (hepatic, pulmonary, and 
hematopoietic) (1). 
Children treated successfully for multisystem Langerhans 
cell histiocytosis (LCH) are at risk for long-term treatment- or 
disease-related sequelae, including diabetes insipidus, neuro-
logic deficits, pulmonary fibrosis, and biliary cirrhosis (2). The 
goal of an optimal therapy that would both improve cure rates 
and decrease the frequency and severity of these late sequelae 
remains to be realized. 
Cirrhosis is a potentially fatal complication of LCH that may 
arise from histiocytic proliferation in the portal triads, leading 
to fibrosis, intrahepatic biliary obstruction, and sclerosing chol-
angitis (3). To our knowledge, there have been no detailed 
I This work was supported in part by the American Lebanese Syrian 
Associated Charities (ALSAC) 
reports of liver transplantation in patients with irreversible 
liver damage secondary to LCH (4). We report a case in which 
an orthotopic transplantation was successful in a child with 
progressive liver cirrhosis. 
A 20-month-old male infant was referred to St. Jude Chil-
dren's Research Hospital in September 1975 with multisystem 
disease involving the skin, liver, spleen, lymph nodes, and 
skeleton. Biopsies of skin and lymph node were diagnostic of 
Langerhans cell histiocytosis (LCH).* A percutaneous liver 
biopsy showed portal triaditis with extensive bile duct prolif-
eration and biliary fibrosis but no infiltrates of Langerhans 
cells (Fig. 1). He was treated initially with prednisone and 
vinblastine, and later with cyclophosphamide. Because of resid-
ual skin disease, methotrexate was administered for 1 year 
beginning in July 1977. The patient then remained off therapy 
for 3 years, after which time the disease recurred in the skin 
and bones. 
After methotrexate failed to produce a second complete re-
sponse, multiple chemotherapeutic agents were tried, including 
6-mercaptopurine, cyclophosphamide, vincristine. and chlor-
ambucil. Craniospinal radiation (800 cGy) was given in March 
* Abbreviation: LCH, Langerhans cell histiocytosis. 
